Popular Trials
Tyrosine Kinase Inhibitor
Imatinib or Dasatinib for Chronic Myeloid Leukemia
Recruiting1 awardPhase 2
Independence, Kansas
This trial looks at two different doses of imatinib mesylate and dasatinib to see how well they work in treating patients with previously untreated chronic phase chronic myelogenous leukemia.
Alkylating agents
Chemotherapy +/− Bevacizumab for Breast Cancer
Recruiting1 awardPhase 3
Fort Smith, Arkansas
This trial is testing doxorubicin hydrochloride, cyclophosphamide, and paclitaxel with or without bevacizumab to see how well they work in treating patients with lymph node-positive or high-risk, lymph node-negative breast cancer.
Popular Filters
Phase 3 Trials
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
Recruiting2 awardsPhase 3
Fort Smith, Arkansas
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Jackson, Mississippi
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
Hormone Therapy
Ovarian Suppression + Tamoxifen/Exemestane for Breast Cancer
Recruiting4 awardsPhase 3
Birmingham, Alabama
This trial is testing whether suppressing ovarian function and combining it with either tamoxifen or exemestane is more effective than tamoxifen alone in treating premenopausal women with hormone-responsive breast cancer.
Trials With No Placebo
Hormone Therapy
Androgen Ablation Therapy + Chemotherapy for Prostate Cancer
Recruiting2 awardsPhase 3
Fort Smith, Arkansas
This trial is studying androgen-ablation therapy and docetaxel to see how well they work compared to androgen-ablation therapy alone in treating patients with metastatic prostate cancer.
Alkylating agents
Surgery, Radiation & Chemotherapy for Early-Stage Hodgkin's Lymphoma
Recruiting2 awardsPhase 2
Little Rock, Arkansas
This trial is studying how well surgery, radiation therapy, and/or combination chemotherapy work in treating young patients with newly diagnosed stage I or stage II lymphocyte predominant Hodgkin disease.
Radiation
Radiation + Chemotherapy for Medulloblastoma
Recruiting2 awardsPhase 3
Jackson, Mississippi
This trial is looking at whether standard-dose radiation therapy, versus reduced-dose, is more effective in children 3-7 years of age who have had surgery for newly diagnosed standard-risk medulloblastoma.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.